The goals of NCORP of the Carolinas are 1. To enroll a minimum of 300 patients annually to NCI Clinical Trials Network (NCTN) trials including cancer prevention, control, screening/post-treatment surveillance, treatment, and imaging clinical trials. 2. To provide community input and assist the NCTN research bases in develop treatment, prevention, control and screening, health related quality of life and cancer care delivery research (CCDR). 3. To attain protocol compliance and submit accurate, timely data. 4. To conduct research by engaging the community, inclusive of minorities and the underserved, and informing the community of advances made through research. 5. To grow as a national leader in the realm of Cancer Care delivery research (CCDR). NCORP of the Carolinas will be perform every phase of clinical trial research sponsored by NCTN groups, including to include, via ITOR (Institution of Translational Oncology Research), translational treatment based on genetic sequencing. GHS Clinical data warehouse system will provide data for CCDR. The Greenville Health System (GHS) Cancer Institute participates in an already robust biospecimen repository and entered membership in the Cancer Genome project (grant accepted July 2013) Collectively the components and sub-components of NCORP of the Carolinas are organizations dedicated to treatment, prevention, supportive care, and system management for study accrual. NCORP of the Carolinas will maximize its research capabilities to ensure progress towards the highest quality of cancer prevention, diagnosis, treatment and care/care delivery.
A robust clinical trials program is relevant to achieving advances in addressing unmet needs of cancer patients in the realm of treatment, cancer prevention, control, screening and surveillance. NCORP will strive to bring improved outcomes to the communities we serve.
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050|
|Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769|
|Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31|
|Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32|